Cancer stem cells enrichment with surface markers CD271 and CD44 in human head and neck squamous cell carcinomas.

Publisher: Irl Press At Oxford University Press Country of Publication: England NLM ID: 8008055 Publication Model: Print Cited Medium: Internet ISSN: 1460-2180 (Electronic) Linking ISSN: 01433334 NLM ISO Abbreviation: Carcinogenesis Subsets: MEDLINE

Publication: Oxford : Irl Press At Oxford University Press
Original Publication: [New York, IRL Press]

Gene Expression Regulation, Neoplastic*; Biomarkers, Tumor/*metabolism ; Head and Neck Neoplasms/*pathology ; Hyaluronan Receptors/*metabolism ; Neoplastic Stem Cells/*pathology ; Nerve Tissue Proteins/*metabolism ; Receptors, Nerve Growth Factor/*metabolism ; Squamous Cell Carcinoma of Head and Neck/*pathology; Animals ; Antineoplastic Agents/pharmacology ; Apoptosis ; Biomarkers, Tumor/genetics ; Cell Proliferation ; Female ; Head and Neck Neoplasms/drug therapy ; Head and Neck Neoplasms/metabolism ; Humans ; Hyaluronan Receptors/genetics ; Male ; Mice ; Mice, Nude ; Neoplastic Stem Cells/drug effects ; Neoplastic Stem Cells/metabolism ; Nerve Tissue Proteins/genetics ; Prognosis ; Receptors, Nerve Growth Factor/genetics ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Squamous Cell Carcinoma of Head and Neck/metabolism ; Survival Rate ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays

Head and neck squamous cell carcinoma (HNSCC) has a poor 5-year survival rate of 50%. One potential reason for treatment failure is the presence of cancer stem cells (CSCs). Several cell markers, particularly CD44, have been used to isolate CSCs. However, isolating a pure population of CSC in HNSCC still remains a challenging task. Recent findings show that normal oral stem cells were isolated using CD271 as a marker. Thus, we investigated the combined use of CD271 and CD44 to isolate an enriched subpopulation of CSCs, followed by their characterization in vitro, in vivo, and in patients' tissue samples. Fluorescent-activated cell sorting was used to isolate CD44+/CD271+ and CD44+/CD271- from two human HNSCC cell lines. Cell growth and self-renewal were measured with MTT and sphere/colony formation assays. Treatment-resistance was tested against chemotherapy (cisplatin and 5-fluorouracil) and ionizing radiation. Self-renewal, resistance, and stemness-related genes expression were measured with qRT-PCR. In vivo tumorigenicity was tested with an orthotopic immunodeficient mouse model of oral cancer. Finally, we examined the co-localization of CD44+/CD271+ in patients' tissue samples. We found that CD271+ cells were a subpopulation of CD44+ cells in human HNSCC cell lines and tissues. CD44+/CD271+ cells exhibited higher cell proliferation, sphere/colony formation, chemo- and radio-resistance, upregulation of CSCs-related genes, and in vivo tumorigenicity when compared to CD44+/CD271- or the parental cell line. These cell markers showed increased expression in patients with the increase of the tumor stage. In conclusion, using both CD44 and CD271 allowed the isolation of CSCs from HNSCC. These enriched CSCs will be more relevant in future treatment and HNSCC progression studies.
(© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)

Sci Rep. 2016 Jul 29;6:30707. (PMID: 27469492)
Leukemia. 2007 May;21(5):926-35. (PMID: 17330101)
Nat Chem Biol. 2007 May;3(5):268-73. (PMID: 17417631)
Cancer Res. 2010 Dec 1;70(23):9969-78. (PMID: 21098716)
J Clin Oncol. 2008 Jun 10;26(17):2839-45. (PMID: 18539962)
Head Neck. 2012 Jan;34(1):42-9. (PMID: 21322081)
Histopathology. 2008 Jul;53(1):62-72. (PMID: 18540978)
Natl Vital Stat Rep. 2018 Jul;67(6):1-77. (PMID: 30248017)
Eur J Cancer. 2013 Jan;49(1):272-80. (PMID: 22770891)
Mol Med Rep. 2017 May;15(5):2521-2529. (PMID: 28447720)
Acta Otolaryngol. 2012 Mar;132(3):314-24. (PMID: 22201277)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
J Oral Pathol Med. 2015 Jul;44(6):410-9. (PMID: 25212757)
J Cutan Pathol. 2010 Mar;37(3):336-43. (PMID: 19615036)
Clin Cancer Res. 2006 Sep 1;12(17):5096-103. (PMID: 16951226)
Neoplasia. 2007 Jun;9(6):471-8. (PMID: 17603629)
Head Neck. 2015 Mar;37(3):317-26. (PMID: 24415402)
Biochem Biophys Res Commun. 2006 Mar 24;341(4):1184-92. (PMID: 16460673)
PLoS One. 2013 Apr 23;8(4):e62002. (PMID: 23626764)
Eur J Cancer. 2006 Jun;42(9):1283-92. (PMID: 16679013)
Med Oncol. 2018 Aug 4;35(9):124. (PMID: 30078069)
Nat Med. 1997 Jul;3(7):730-7. (PMID: 9212098)
F1000Prime Rep. 2014 Jun 02;6:44. (PMID: 24991421)
Indian J Dent Res. 2018 May-Jun;29(3):333-340. (PMID: 29900918)
Int J Clin Oncol. 2013 Feb;18(1):154-63. (PMID: 22170235)
Stem Cell Res Ther. 2010 Dec 14;1(5):39. (PMID: 21156086)
Exp Neurol. 2008 Oct;213(2):381-7. (PMID: 18675804)
Tumour Biol. 2018 May;40(5):1010428318780859. (PMID: 29888653)
Nat Rev Cancer. 2008 Oct;8(10):755-68. (PMID: 18784658)
J Oral Maxillofac Surg. 2010 Jun;68(6):1290-5. (PMID: 20363547)
Cancer Res. 2006 Jun 15;66(12):6063-71. (PMID: 16778178)
Head Neck. 2012 Jun;34(6):894-9. (PMID: 21850700)
J Neurochem. 2009 Jul;110(1):295-306. (PMID: 19457114)
J Dent Res. 2012 Apr;91(4):334-40. (PMID: 21933937)
Sci Rep. 2017 Feb 21;7:43008. (PMID: 28220856)
Cancer Res. 2011 Apr 15;71(8):3098-109. (PMID: 21393506)
J Clin Pharmacol. 2005 Aug;45(8):872-7. (PMID: 16027397)
Nat Rev Cancer. 2005 Sep;5(9):744-9. (PMID: 16148886)
Oncol Lett. 2013 Mar;5(3):787-792. (PMID: 23426586)
Nature. 2009 Apr 9;458(7239):780-3. (PMID: 19194462)
Oncogenesis. 2017 Jan 23;6(1):e291. (PMID: 28112719)
Nat Rev Cancer. 2008 Jul;8(7):545-54. (PMID: 18511937)
Arch Otolaryngol Head Neck Surg. 1998 Jun;124(6):637-40. (PMID: 9639472)
Neoplasia. 2011 Oct;13(10):991-1004. (PMID: 22028624)
BMC Cancer. 2009 Jan 10;9:9. (PMID: 19134212)
Saudi Dent J. 2019 Oct;31(4):395-416. (PMID: 31700218)
Oncotarget. 2014 Dec 15;5(23):11986-97. (PMID: 25230277)
Stem Cells. 2007 Mar;25(3):628-38. (PMID: 17110619)
Am J Clin Pathol. 1989 Oct;92(4):415-23. (PMID: 2552791)
Asian Pac J Cancer Prev. 2013;14(10):5579-87. (PMID: 24289547)
J Clin Oncol. 1999 Aug;17(8):2419-28. (PMID: 10561305)
Oncotarget. 2014 Aug 30;5(16):6854-66. (PMID: 25149537)
Oncogene. 2003 Jun 26;22(26):4017-26. (PMID: 12821936)

119585 Canada CIHR

0 (Antineoplastic Agents)
0 (Biomarkers, Tumor)
0 (CD44 protein, human)
0 (Hyaluronan Receptors)
0 (NGFR protein, human)
0 (Nerve Tissue Proteins)
0 (Receptors, Nerve Growth Factor)

Date Created: 20191120 Date Completed: 20201027 Latest Revision: 20210618

20240829

PMC7298622

10.1093/carcin/bgz182

31742606